Sangui BioTech International Files S-1 Registration Statement with the SEC

WITTEN, Germany--(BUSINESS WIRE)--

Sangui Biotech International, Inc. has filed a preliminary S-1 Registration Statement with the Securities and Exchange Commission. It is being expected that the SEC will declare the Prospectus effective within the next couple of weeks. The exact timeline depends on SEC approval procedures which cannot be anticipated by the company. The S-1 becoming effective is prerequisite for Sangui to start drawing upon the financial framework agreement with US investor Southridge as announced on May 12, 2015.

Under the terms of this agreement Sangui Biotech International, Inc. acquired the right to sell shares to a fund of Southridge LLC, an institutional investor, located in Connecticut and New York in the amount of up to $5 million over a period of three years.

This financial instrument is one element of Sangui's plan to carry out the preclinical phase of its SBT102 product which underwent successful preclinical testing. SBT102 developed by SanguiBioTech improves the oxygen supply of vital organs. It's intraperitoneal application is an innovative and effective therapy to avoid tissue hypoxemia in cases of septic shock. It can be expected that the restoration of intestinal oxygenation will have an impact on tissue integrity and eventually on patient survival.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies SGBI. Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges SBH. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150626005206/en/